Sold as Gantrisin. Every FDA application for this active ingredient: 3 branded and 1 generic.
As of Nov 15, 2026, FDA lists 4 applications for Sulfisoxazole Diolamine (sold as Gantrisin), with 0 new uses approved and 0 published complete response letters.
| Jan 22, 1975 | Sulfisoxazole DiolamineANDA 84148 | Sola Barnes Hind | 0 | Discontinued |
| — | GantrisinNDA 6917 | Roche | 0 | Discontinued |
| — | GantrisinNDA 7757 | Roche | 0 | Discontinued |
| — | GantrisinNDA 8414 | Roche | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Roche